{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:48:51Z","timestamp":1784191731669,"version":"3.55.0"},"reference-count":0,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[1993,2,1]],"date-time":"1993-02-01T00:00:00Z","timestamp":728524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1993,2]]},"abstract":"<jats:p>The bacteriological and clinical efficacies of cefuroxime axetil suspension (20 mg\/kg of body weight per day in two divided doses) were compared with those of penicillin V suspension (50 mg\/kg\/day in three divided doses) in a multicenter, randomized, evaluator-blinded study. Children aged 2 to 13 years with clinical signs and symptoms of acute pharyngitis and a positive throat culture for group A beta-hemolytic streptococci (GABHS) were eligible. Patients were assessed and samples from the throat for culture were obtained at the time of diagnosis, 3 to 7 days after the initiation of treatment, and 4 to 8 days and 19 to 25 days after the completion of 10 days of therapy. Of the 385 evaluable patients, GABHS were eradicated from 244 of 259 (94.2%) cefuroxime-treated patients and 106 of 126 (84.1%) penicillin-treated patients (P = 0.001). Complete resolution of the signs and symptoms present at the time of diagnosis was achieved in 238 of 259 (91.9%) cefuroxime-treated patients and 102 of 126 (81.0%) penicillin-treated patients (P = 0.001). Potential drug-related adverse events were reported in 7.0 and 3.2% of the cefuroxime- and penicillin-treated patients, respectively (P = 0.078). In the present study, cefuroxime axetil suspension given twice daily resulted in significantly greater bacteriological and clinical efficacies than those of penicillin V suspension given three times daily to pediatric patients with acute pharyngitis and a positive throat culture for GABHS.<\/jats:p>","DOI":"10.1128\/aac.37.2.159","type":"journal-article","created":{"date-parts":[[2012,6,28]],"date-time":"2012-06-28T00:05:50Z","timestamp":1340841950000},"page":"159-163","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":34,"title":["Efficacy of cefuroxime axetil suspension compared with that of penicillin V suspension in children with group A streptococcal pharyngitis"],"prefix":"10.1128","volume":"37","author":[{"suffix":"3rd","given":"W M","family":"Gooch","sequence":"first","affiliation":[{"name":"Primary Children's Medical Center, Salt Lake City, Utah 84113-1100."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S E","family":"McLinn","sequence":"additional","affiliation":[{"name":"Primary Children's Medical Center, Salt Lake City, Utah 84113-1100."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G H","family":"Aronovitz","sequence":"additional","affiliation":[{"name":"Primary Children's Medical Center, Salt Lake City, Utah 84113-1100."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M E","family":"Pichichero","sequence":"additional","affiliation":[{"name":"Primary Children's Medical Center, Salt Lake City, Utah 84113-1100."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Kumar","sequence":"additional","affiliation":[{"name":"Primary Children's Medical Center, Salt Lake City, Utah 84113-1100."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E L","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Primary Children's Medical Center, Salt Lake City, Utah 84113-1100."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M J","family":"Ossi","sequence":"additional","affiliation":[{"name":"Primary Children's Medical Center, Salt Lake City, Utah 84113-1100."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.37.2.159","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.37.2.159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:32:31Z","timestamp":1645457551000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.37.2.159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,2]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1993,2]]}},"alternative-id":["10.1128\/AAC.37.2.159"],"URL":"https:\/\/doi.org\/10.1128\/aac.37.2.159","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993,2]]},"assertion":[{"value":"1993-02-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}